COST-EFFECTIVENESS OF SUBCUTANEOUS IMMUNOTHEREAPY IN ALLERGIC RHINITIS USING ONE OR MORE ALLERGENS - AN ANALYSIS LONG OVERDUE
Author(s)
Kiel MA1, Röder E2, Gerth van Wijk R2, Rutten - Van Mölken MP1
1Erasmus University, Rotterdam, The Netherlands, 2Erasmus Medical Center, Rotterdam, The Netherlands
OBJECTIVES Allergic rhinitis – hay fever and mite hypersensitivity - is a prevalent and increasingly common condition, causing considerable morbidity and economic burden to society. A minority of patients have an indication for subcutaneous immunotherapy (SCIT). SCIT using extracts of tree pollen, grass pollen and/or house dust mite is common practice in The Netherlands, Europe and beyond. SCIT is widely reimbursed, but very few prospective cost-effectiveness studies have been done. METHODS An open-label, 2-year, multicenter, randomized controlled trial with two parallel treatment arms was performed, comparing SCIT + usual care (UC) with UC alone, using online resource use and labor productivity questionnaires, and electronic versions of EQ-5D®, SF-36® and a global subjective assessment of symptoms (GA). Primary endpoints were the costs per QALY, costs per successfully treated patient and the cost per additional symptom-free day. A Generalized Estimation Equation (GEE) model was estimated with mean two-week health care/societal costs as dependent variable, followed by a 1000-iteration bootstrap procedure. RESULTS A total of 183 adult patients aged 18 to 45 years with persistent moderate to severe allergic rhinitis due to one (43%) or more (57%) allergies (93 SCIT+UC, 90 UC) were included. There were no significant differences at baseline. The percentage of patients that reported to be treated successfully was 36% in SCIT and 20% in UC after two years. Other health outcomes did not differ between SCIT and Usual Care. Two-year costs of SCIT were 2946 Euro per patient. There was no difference in other costs. Cost per additional successfully treated patient were about 15,000 Euro. For the other outcomes, SCIT was dominated by UC. CONCLUSIONS This study could not support the cost-effectiveness of SCIT. A restriction in the indication of SCIT to patients with severe persistent rhinitis, not sufficiently responsive to maximum symptomatic therapy may improve cost-effectiveness.
Conference/Value in Health Info
2014-11, ISPOR Europe 2014, Amsterdam, The Netherlands
Value in Health, Vol. 17, No. 7 (November 2014)
Code
PRS55
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Respiratory-Related Disorders